Loading company
Latest annual · FY2023
Millions- Net income
- (10)
Latest quarter · Q4 FY2023
Millions- Net income
- (10)
Medicenna Therapeutics Corp. (MDNAF) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Net income | -CA$10 million | -CA$22.6 million | 20-F 2023-06-27 · proof | |
| Cash from operating activities | -CA$23.6 million | -CA$15.3 million | 20-F 2022-06-22 · proof | |
| Total assets | CA$36.4 million | CA$23.5 million | +55.4% | 20-F 2023-06-27 · proof |
| Total liabilities | CA$7 million | CA$2.6 million | +165.5% | 20-F 2023-06-27 · proof |
| Cash and cash equivalents | CA$33.6 million | CA$20.5 million | +63.6% | 20-F 2023-06-27 · proof |
- What was Medicenna Therapeutics Corp. (MDNAF)'s net income in fiscal 2023?
- Medicenna Therapeutics Corp. (MDNAF) reported net income of -CA$10 million for fiscal 2023 (the year ended Mar 31, 2023), against -CA$22.6 million the year before. Source: the 20-F filed with the SEC on Jun 27, 2023. SEC
- What was Medicenna Therapeutics Corp. (MDNAF)'s cash from operating activities in fiscal 2022?
- Medicenna Therapeutics Corp. (MDNAF) reported cash from operating activities of -CA$23.6 million for fiscal 2022 (the year ended Mar 31, 2022), against -CA$15.3 million the year before. Source: the 20-F filed with the SEC on Jun 22, 2022. SEC
- What are Medicenna Therapeutics Corp. (MDNAF)'s total assets?
- As of Mar 31, 2023, Medicenna Therapeutics Corp. (MDNAF) reported total assets of CA$36.4 million, against CA$23.5 million a year earlier (+55.4%). Source: the 20-F filed with the SEC on Jun 27, 2023. SEC
- What are Medicenna Therapeutics Corp. (MDNAF)'s total liabilities?
- As of Mar 31, 2023, Medicenna Therapeutics Corp. (MDNAF) reported total liabilities of CA$7 million, against CA$2.6 million a year earlier (+165.5%). Source: the 20-F filed with the SEC on Jun 27, 2023. SEC
- What are Medicenna Therapeutics Corp. (MDNAF)'s cash and cash equivalents?
- As of Mar 31, 2023, Medicenna Therapeutics Corp. (MDNAF) reported cash and cash equivalents of CA$33.6 million, against CA$20.5 million a year earlier (+63.6%). Source: the 20-F filed with the SEC on Jun 27, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MDNAF&period_type=annual&limit=5"Information only, not investment advice.